دورية أكاديمية
أعرض في EDS

miRNA-mediated control of exogenous OCT4 during mesenchymal-epithelial transition increases measles vector reprogramming efficiency.

التفاصيل البيبلوغرافية
العنوان: miRNA-mediated control of exogenous OCT4 during mesenchymal-epithelial transition increases measles vector reprogramming efficiency.
المؤلفون: Rallabandi R; Virology and Gene Therapy Graduate Track, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905, USA.; Regenerative Sciences PhD Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905, USA., Sharp B; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA., Cruz C; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA., Wang Q; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA., Locsin A; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA., Driscoll CB; Virology and Gene Therapy Graduate Track, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905, USA., Lee E; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA., Nelson T; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester MN 55905, USA., Devaux P; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.; Virology and Gene Therapy Graduate Track, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905, USA.; Regenerative Sciences PhD Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905, USA.
المصدر: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2021 Nov 29; Vol. 24, pp. 48-61. Date of Electronic Publication: 2021 Nov 29 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101624857 Publication Model: eCollection Cited Medium: Print ISSN: 2329-0501 (Print) Linking ISSN: 23290501 NLM ISO Abbreviation: Mol Ther Methods Clin Dev Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2017- : Cambridge, MA : Cell Press
Original Publication: New York, NY : Nature Publishing Group, [2014]-
مستخلص: OCT4 is a key mediator of induced pluripotent stem cell (iPSC) reprogramming, but the mechanistic insights into the role of exogenous OCT4 and timelines that initiate pluripotency remain to be resolved. Here, using measles reprogramming vectors, we present microRNA (miRNA) targeting of exogenous OCT4 to shut down its expression during the mesenchymal to the epithelial transition phase of reprogramming. We showed that exogenous OCT4 is required only for the initiation of reprogramming and is dispensable for the maturation stage. However, the continuous expression of SOX2 , KLF4 , and c-MYC is necessary for the maturation stage of the iPSC. Additionally, we demonstrate a novel application of miRNA targeting in a viral vector to contextually control the vector/transgene, ultimately leading to an improved reprogramming efficiency. This novel approach could be applied to other systems for improving the efficiency of vector-induced processes.
Competing Interests: P.D., R.R., Q.W., and C.B.D. are inventors of an IP that was licensed by National Resilience Inc, and for which they may receive payments. The other authors declared no conflict of interest.
(© 2021 The Authors.)
References: Stem Cell Reports. 2014 Nov 11;3(5):915-29. (PMID: 25418733)
Cell. 2009 Jan 23;136(2):364-77. (PMID: 19167336)
Oncotarget. 2015 Apr 20;6(11):8474-90. (PMID: 25893379)
Neoplasia. 2014 Apr;16(4):279-90.e1-5. (PMID: 24746361)
Curr Opin Virol. 2015 Aug;13:40-8. (PMID: 25863717)
Sci Adv. 2017 Feb 03;3(2):e1602350. (PMID: 28168220)
Cell. 2017 Jan 26;168(3):442-459.e20. (PMID: 28111071)
Development. 2016 Jan 1;143(1):15-23. (PMID: 26657769)
Cell Regen. 2015 Nov 11;4:10. (PMID: 26566431)
Genes (Basel). 2011 Feb 25;2(1):229-59. (PMID: 24710147)
Nature. 2007 Jul 19;448(7151):313-7. (PMID: 17554338)
Cell Stem Cell. 2010 Jul 2;7(1):51-63. (PMID: 20621050)
Cancer Gene Ther. 2014 Sep;21(9):373-80. (PMID: 25145311)
Cell Stem Cell. 2019 Dec 5;25(6):737-753.e4. (PMID: 31708402)
PLoS One. 2015 Apr 13;10(4):e0122108. (PMID: 25875172)
PLoS One. 2017 Dec 27;12(12):e0190275. (PMID: 29281720)
Gene Ther. 2019 May;26(5):151-164. (PMID: 30718755)
Cell Mol Life Sci. 2006 Feb;63(3):268-84. (PMID: 16389449)
Nat Biotechnol. 2011 May;29(5):443-8. (PMID: 21490602)
Gene. 2019 Feb 20;686:146-159. (PMID: 30472380)
Cell. 2006 Aug 25;126(4):663-76. (PMID: 16904174)
Cell Stem Cell. 2010 Jul 2;7(1):64-77. (PMID: 20621051)
Cell Rep. 2012 Feb 23;1(2):99-109. (PMID: 22832160)
Cancer Cell. 2009 Mar 3;15(3):165-6. (PMID: 19249674)
Nat Genet. 2008 Dec;40(12):1478-83. (PMID: 18978791)
Cell Stem Cell. 2012 Dec 7;11(6):769-82. (PMID: 23217423)
Sci Rep. 2017 Apr 10;7:46315. (PMID: 28393933)
J Clin Invest. 2009 Jan;119(1):157-68. (PMID: 19033646)
Glia. 2009 Apr 15;57(6):667-79. (PMID: 18942755)
Mol Ther Oncolytics. 2018 Apr 12;9:30-40. (PMID: 29988512)
Curr Opin Virol. 2020 Apr;41:85-97. (PMID: 32861945)
Mol Ther Methods Clin Dev. 2019 Jan 08;12:223-232. (PMID: 30775404)
Mol Ther. 2020 Jan 8;28(1):129-141. (PMID: 31677955)
World J Exp Med. 2016 May 20;6(2):37-54. (PMID: 27226955)
Nat Rev Genet. 2009 Aug;10(8):578-85. (PMID: 19609263)
PLoS Pathog. 2016 Dec 9;12(12):e1006058. (PMID: 27936158)
Nat Rev Dis Primers. 2016 Jul 14;2:16049. (PMID: 27411684)
Cell. 2012 Nov 21;151(5):994-1004. (PMID: 23159369)
Nat Rev Genet. 2010 Sep;11(9):597-610. (PMID: 20661255)
Dev Biol. 2012 Nov 15;371(2):136-45. (PMID: 22819673)
Br J Cancer. 2006 Mar 27;94(6):776-80. (PMID: 16495913)
J Biol Chem. 2011 Sep 23;286(38):33520-32. (PMID: 21799003)
Cell. 1998 Oct 30;95(3):379-91. (PMID: 9814708)
Stem Cells. 2010 Oct;28(10):1728-40. (PMID: 20715179)
Methods Mol Biol. 2011;767:67-85. (PMID: 21822868)
Trends Cell Biol. 2014 May;24(5):275-84. (PMID: 24370212)
ACS Appl Mater Interfaces. 2019 Sep 18;11(37):34376-34384. (PMID: 31490644)
Cell. 1981 May;24(2):519-29. (PMID: 7237558)
Nat Biotechnol. 2007 Dec;25(12):1457-67. (PMID: 18026085)
Exp Cell Res. 2005 Oct 1;309(2):345-57. (PMID: 16054130)
Oncogene. 2017 Jan 5;36(1):24-34. (PMID: 27270433)
Nat Rev Genet. 2011 Feb;12(2):99-110. (PMID: 21245828)
Stem Cells Dev. 2014 Jun 15;23(12):1285-300. (PMID: 24524728)
Stem Cell Res. 2015 Jan;14(1):39-53. (PMID: 25506910)
Cell Stem Cell. 2014 Sep 4;15(3):392. (PMID: 28903021)
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11602-7. (PMID: 20534548)
J Virol. 2014 Sep;88(18):10851-63. (PMID: 25008930)
Nature. 2008 Jul 3;454(7200):49-55. (PMID: 18509334)
Cell Reprogram. 2018 Feb;20(1):17-26. (PMID: 29412740)
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12759-64. (PMID: 19549847)
Science. 2007 Dec 21;318(5858):1917-20. (PMID: 18029452)
Stem Cell Res Ther. 2015 Mar 26;6:48. (PMID: 25889591)
معلومات مُعتمدة: R01 HL147852 United States HL NHLBI NIH HHS; T32 AI132165 United States AI NIAID NIH HHS; R21 AI105233 United States AI NIAID NIH HHS; P30 CA015083 United States CA NCI NIH HHS; R56 HL147852 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: OCT4; iPSC; measles virus; mesenchymal-epithelial transition; microRNA targeting; reprogramming; viral vectors
تواريخ الأحداث: Date Created: 20220103 Latest Revision: 20240510
رمز التحديث: 20240510
مُعرف محوري في PubMed: PMC8683617
DOI: 10.1016/j.omtm.2021.11.012
PMID: 34977272
قاعدة البيانات: MEDLINE
الوصف
تدمد:2329-0501
DOI:10.1016/j.omtm.2021.11.012